26
Participants
Start Date
September 30, 2013
Primary Completion Date
September 8, 2015
Study Completion Date
September 8, 2015
Laboratory Biomarker Analysis
Correlative studies
Trametinib
Given PO
Uprosertib
Given PO
Memorial Sloan Kettering Cancer Center, New York
Thomas Jefferson University Hospital, Philadelphia
Fox Chase Cancer Center, Philadelphia
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
University of Virginia Cancer Center, Charlottesville
Virginia Commonwealth University/Massey Cancer Center, Richmond
Carolinas Medical Center/Levine Cancer Institute, Charlotte
Medical University of South Carolina, Charleston
Augusta University Medical Center, Augusta
University of Kentucky/Markey Cancer Center, Lexington
Ohio State University Comprehensive Cancer Center, Columbus
Case Western Reserve University, Cleveland
Hillcrest Hospital Cancer Center, Mayfield Heights
Cleveland Clinic Foundation, Cleveland
University of Chicago Comprehensive Cancer Center, Chicago
Washington University School of Medicine, St Louis
University of Oklahoma Health Sciences Center, Oklahoma City
M D Anderson Cancer Center, Houston
University of New Mexico Cancer Center, Albuquerque
Hartford Hospital, Hartford
The Hospital of Central Connecticut, New Britain
Women and Infants Hospital, Providence
Collaborators (1)
NRG Oncology
OTHER
National Cancer Institute (NCI)
NIH